The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 InterMune Inc.  (ITMN) Trade Now »     Rate ITMN  -  Discuss ITMN  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate ITMN:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

ITMN: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on ITMN ... Graphic_rating_buy ITMN
Foto
62%
 -4.72%
in 251 days
InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The companyÂ’s product candidates include Pirfenidone, which is in phase III clinical trials for the treatment of idiopathic pulmonary fibrosis; and ITMN-191, a hepatitis C virus protease inhibitor that is in Phase Ib clinical trials to treat patients with HCV infections. It has license and collaboration a...
By  Marian Filo   (-24.55%  risk: aggressive)  03/02/09 Comment












From the Blogosphere

Stock Market - Day Trades:
Cc_logo
49%

As we searched the stocks in the top performing industries and the sectors
with new technical analysis buy signals, we found no stocks that we were
comfortable writing about. So today we will focus on stocks that are day
trade candidates. Starting tomorrow, this will be a regular feature for our subscribers (subscribe now) in the Correct Call Calendar.

When you are day trading, there are rules to live by.

<>
  • Try to take positions that correspond with the overall market direction; buy on up days and short on down days.
  • Don’t hold anything overnight.
    • <>If you do hold trades overnight, don’t let sm<><><><><><><><><><><><>< /><><><><><><><><>< />...
    By  The Correct Call   (-1.21%  risk: moderate)  05/28/09 Comment


    What Happened In The Market Today…3 Feb 09
    Stop
    56%
    What’s Happening In The Market Now..
    <>
  • Stocks popped up at the open this morning after Citigroup (C) announced a $36.5 billion lending plan.
  • Consumers frightened by the prospect of losing their jobs stayed away from auto showrooms again in January and sent U.S. car and truck sales falling 37 percent.
    • <>The National Association of Realtors said buyers stepped in to snap up properties at steep discounts in December, especially in the South and Midwest. Its seasonally adjusted index of pending sales for preowned homes rose 6.3 percent in the final month of the year from revised figures in Nov...
    By  s J   (-18.05%  risk: aggressive)  02/04/09 Comment


    Intermune (ITMN) rises 35%

    Shares of Biotechnology company InterMune Inc (nasdaq: ITMN) are up 35% after announcing a late-stage study of its investigational treatment for a potentially fatal lung disease met the main goal, even as another late-stage trial of the same drug failed.

    Investors were extremely pessimistic about the outcome of the study given that no drug succeeded in the disease before, Canaccord Adams analyst Adam Cutler said by phone.

    People now think that there is a chance of the drug getting approved, when many assumed it did not have much chance before today.

    read more
    By  theStockMasters   (-69.11%  risk: moderate)  02/03/09 Comment


    Options Update: Developmental companies' volatility elevated into data

    Filed under: Options

    Intermune (NASDAQ: ITMN) closed at $11.72. ITMN's Pirfenidone Capacity data is expected soon. ITMN February 12.5 straddle is priced at $7.40, April 12.5 straddle is at $9.80 and July 12.5 straddle is priced at $14.10 according to Track Data, suggesting large price movement.

    Sequenom (NASDAQ: SQNM) closed at $23.09. SQNM will present Down's syndrome data after the market close today. SQNM February option implied volatility is at140; March is at 120; above its 26-week average of 103, according to Track Data, suggesting larger price movement.

    <>Geron (NASDAQ: GERN), a biopharma...
    By  Paul Foster   (+0.00%)  01/28/09 Comment


    A Calendar of Expected Clinical Trial Results
    Mikerun
    73%


    The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.

    See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in the form of clinical trial results:

    Sequenom (SQNM) is set for a busy month after its $41...
    By  Mike Havrilla   (+1.04%  risk: conservative)  01/11/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +35.25% 368
    2 Gerald Greene 18.14 +70.90% 206
    3 stockmarketfunding.com 17.66 +25.78% 53
    4 akiralegrand 13.47 +14.32% 60
    5 anup2104 12.13 +69.23% 34


    POPULAR STOCKS
    Symbol Company Name Sentiment
    SIRI Sirius Satellite Radio Inc
    BA The Boeing Company
    V Visa Inc
    IBM International Business Machines Corp
    AMD Advanced Micro Devices Inc
    FSLR First Solar Inc.

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on ITMN

    Visit streetinsider.com


    Discussion Wall + Add  
    amritadas   (+0.00%)
    A FREE report on upcoming FDA decision for small ca.. - FDA decision date coming up this month for small cap company's Pain drug. If the FDA approves the drug, the peak sales could reach over 200% of the com...
    +   0 replies

    amritadas   (+0.00%)
    Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
    +   0 replies


    More Resources

    Graphic_arrow1 About InterMune Inc. - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch